Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs

References

• Mantle Cell Lymphoma. Lymphoma Research Foundation. Accessed November 28, 2022. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/mantle-cell-lymphoma/.
   Google Scholar
• Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–798. doi:10.1002/cncr.23608
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531. doi:10.1056/NEJMoa1200920
   PubMed Web of Science ®Google Scholar
• Sharman J, Kabadi SM, Clark J, et al. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–746. doi:10.1111/bjh.16922
   PubMed Web of Science ®Google Scholar
• Karmali R, Switchenko JM, Goyal S, et al. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021;96(11):1374–1384. doi:10.1002/ajh.26306
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213. doi:10.1200/JCO.2008.19.6121
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. doi:10.1182/bloodadvances.2020004074
   PubMed Web of Science ®Google Scholar
• Tbakhi B, Reagan PM. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Ther Adv Hematol. 2022;13:204062072210807. doi:10.1177/20406207221080738
   Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. doi:10.1016/S0140-6736(17)33108-2
   PubMed Web of Science ®Google Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. doi:10.1016/S0140-6736(21)00224-5
   PubMed Web of Science ®Google Scholar
• Jiang VC, Liu Y, Jordan A, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14(1):132. doi:10.1186/s13045-021-01143-w
   PubMed Web of Science ®Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71. doi:10.3324/haematol.2018.198812
   PubMed Web of Science ®Google Scholar
• Wang ML, Barrientos JC, Furman RR, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1(1):1–11 (see https://evidence.nejm.org/doi/pdf/) EVIDoa2100001. doi:10.1056/EVIDoa2100001
   Google Scholar
• Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi:10.1056/NEJMoa2201817
   PubMed Web of Science ®Google Scholar
• Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. 2022 ASH annual meeting and exposition. Presented December 11, 2022.
   Google Scholar
• Kabadi SM, Goyal RK, Nagar SP, et al. Treatment ­patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810. doi:10.1002/cam4.2268
   PubMed Web of Science ®Google Scholar
• Ghosh N, Emond B, Lafeuille MH, et al. Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study. Clin Ther. 2021;43(8):1285–1299. doi:10.1016/j.clinthera.2021.06.012
   PubMed Web of Science ®Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, et al. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019;60(4):955–963. doi:10.1080/10428194.2018.1509320
   PubMed Web of Science ®Google Scholar
• Kabadi SM, Byfield SD, Le L, et al. Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a Real-World retrospective cohort study. Anticancer Res. 2021;41(2):927–936. doi:10.21873/anticanres.14846
   PubMed Web of Science ®Google Scholar
• Weaver JA, Peng Y, Ji Y, et al. A medicare database analysis of practice patterns in patients with mantle cell lymphoma. J Geriatr Oncol. 2021;12(6):894–901. doi:10.1016/j.jgo.2020.12.013
   PubMed Web of Science ®Google Scholar
• Goyal RK, Jain P, Nagar SP, et al. Real-world evidence on survival, adverse events, and health care burden in medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62(6):1325–1334. doi:10.1080/10428194.2021.1919662
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines insights: b -Cell lymphomas, version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218–1230. doi:10.6004/jnccn.2021.0054
   PubMed Web of Science ®Google Scholar
• SAS: Analytics, Artificial Intelligence and Data Management | SAS. Accessed November 30, 2022. https://www.sas.com/en_us/home.html.
   Google Scholar
• Lipsky A, Martin P. Bendamustine-rituximab in mantle cell lymphoma. Lancet Haematol. 2017;4(1):e2–e3. doi:10.1016/S2352-3026(16)30187-9
   PubMed Web of Science ®Google Scholar
• Ye H, Desai A, Zeng D, et al. Frontline treatment for older patients with mantle cell lymphoma. Oncologist. 2018;23(11):1337–1348. doi:10.1634/theoncologist.2017-0470
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl S, Puckett JT, Bagchi I, et al. Barriers and solutions to improve access for chimeric antigen receptor therapies. Immunotherapy. Published. 2022;14(9):741–753. doi:10.2217/imt-2022-0037
   Web of Science ®Google Scholar
• Freed M. 2021. Seven in Ten Medicare Beneficiaries Did Not Compare Plans During Past Open Enrollment Period. KFF. Published October 13, 2021. Accessed November 29, 2021. https://www.kff.org/medicare/issue-brief/seven-in-ten-medicare-beneficiaries-did-not-compare-plans-during-past-open-enrollment-period/.
   Google Scholar